AbCellera Biologics Inc (ABCL) concluded trading on Wednesday at a closing price of $3.53, with 11.02 million shares of worth about $38.92 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 17.28% during that period and on January 22, 2025 the price saw a gain of about 15.36%. Currently the company’s common shares owned by public are about 295.16M shares, out of which, 221.93M shares are available for trading.
Stock saw a price change of 27.44% in past 5 days and over the past one month there was a price change of 31.23%. Year-to-date (YTD), ABCL shares are showing a performance of 20.48% which decreased to -32.63% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $2.34 but also hit the highest price of $5.62 during that period. The average intraday trading volume for AbCellera Biologics Inc shares is 2.75 million. The stock is currently trading 16.85% above its 20-day simple moving average (SMA20), while that difference is up 20.92% for SMA50 and it goes to 14.55% higher than SMA200.
AbCellera Biologics Inc (NASDAQ: ABCL) currently have 295.16M outstanding shares and institutions hold larger chunk of about 34.56% of that.
The stock has a current market capitalization of $1.04B and its 3Y-monthly beta is at 0.41. It has posted earnings per share of -$0.60 in the same period. It has Quick Ratio of 9.34 while making debt-to-equity ratio of 0.07. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for ABCL, volatility over the week remained 8.86% while standing at 7.14% over the month.
Analysts are in expectations that AbCellera Biologics Inc (ABCL) stock would likely to be making an EPS of -0.15 in the current quarter, while forecast for next quarter EPS is -0.17 and it is -0.68 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.19 which is -0.1 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.16 in the same quarter a year ago. Stock’s fiscal year EPS is expected to drop by -15.13% while it is estimated to increase by 3.35% in next year.
Coverage by The Benchmark Company stated AbCellera Biologics Inc (ABCL) stock as a Buy in their note to investors on February 22, 2024, suggesting a price target of $9 for the stock. Stock get an Overweight rating from Piper Sandler on October 13, 2023.
